Publications

The UCLA Division of Dermatology frequently shares research and insights in top-tier academic journals. Read their latest articles here.

August 2026

1. Peng DS, Shen A, Smart C, Galamgam J. Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use. JAAD Case Rep. 2026 Jun 12;74:247-250. doi: 10.1016/j.jdcr.2026.06.006. PMID: 42541308; PMCID: PMC13427499.
2. Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. Am J Clin Dermatol. 2026 Aug 7. doi: 10.1007/s40257-026-01055-w. Epub ahead of print. PMID: 42563042.
3. Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. Am J Clin Dermatol. 2026 Aug 7. doi: 10.1007/s40257-026-01055-w. Epub ahead of print. PMID: 42563042.
4. Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki M. Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials. J Dermatol. 2026 Aug 5. doi: 10.1111/1346-8138.70392. Epub ahead of print. PMID: 42557591.
5. Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA, Barker JN, Weidinger S, Modlin RL, Betz RC, Khanna D, Varga J, Kahlenberg JM, He K, Elder JT, Zhou X, Gudjonsson JE, Tsoi LC. Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes. J Allergy Clin Immunol. 2026 Aug;158(2):470-481. doi: 10.1016/j.jaci.2026.05.013. Epub 2026 May 26. PMID: 42203178.
6. Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280. doi: 10.7759/cureus.112280. PMID: 42569625; PMCID: PMC13450657.
7. Hau JT, Martin SJ, Roosa CA, Deshayes S, Hanke CW. Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study. Dermatol Surg. 2026 Aug 11. doi: 10.1097/DSS.0000000000005306. Epub ahead of print. PMID: 42574233.
8. Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. J Dermatolog Treat. 2026 Dec;37(1):2694924. doi: 10.1080/09546634.2026.2694924. Epub 2026 Aug 11. PMID: 42581417.
9. Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther F, Thaçi D. Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis. Dermatol Ther (Heidelb). 2026 Aug 20. doi: 10.1007/s13555-026-01869-w. Epub ahead of print. PMID: 42622791.
10. Kasperkiewicz M, Xu J, Thapa M, Culton DA, Curman P, Hashimoto T, Meijer JM, Patsatsi A, Tomayko MM, Lehman JS, Schmidt E. Diagnosis and management of anti-p200 pemphigoid: Perspectives of international dermatologists with expertise in immunobullous diseases. J Am Acad Dermatol. 2026 Aug 27:S0190-9622(26)03402-X. doi: 10.1016/j.jaad.2026.08.080. Epub ahead of print. PMID: 42660435.